LOX-1在中药活性化合物抗动脉粥样硬化中的调节作用:当前知识和新见解

YAO Si-jie; LAN Tao-hua; ZHANG Xin-yu; ZENG Qiao-huang; XU Wen-jing; LI Xiao-qing; HUANG Gui-bao; LIU Tong; LYU Wei-hui; JIANG Wei

doi:10.1007/s11655-022-3621-9

Your Location：

Home >

Browse articles >

LOX-1在中药活性化合物抗动脉粥样硬化中的调节作用:当前知识和新见解

Review | Updated：2023-02-01

- LOX-1在中药活性化合物抗动脉粥样硬化中的调节作用:当前知识和新见解
- LOX-1 Regulation in Anti-atherosclerosis of Active Compounds of Herbal Medicine: Current Knowledge and the New Insight
- 中国结合医学杂志（英文版） 2023年29卷第2期页码：179-185
- Affiliations：
  
  1.State Key Laboratory of Dampness Syndrome of Chinese Medicine, Department of Cardiology, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou (510020), China
  2.Guangdong Provincial Key Laboratory of Chinese Medicine for Prevention and Treatment of Refractory Chronic Diseases, Guangzhou (510020), China
  3.The Second Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou (510405), China
- Author bio：
  
  Dr. JIANG Wei, E-mail: jiangwei@gzucm.edu.cn
- Funds：
  
  the National Natural Science Foundation of China(81874432;82074369);Science and Technology Planning Project of Guangdong Province(No. 2018B030322012)
- DOI：10.1007/s11655-022-3621-9
  中图分类号：
- 纸质出版日期：2023-02，
  
  网络出版日期：2022-11-07，
  
  录用日期：2022-07-01
Scan for full text
LOX-1在中药活性化合物抗动脉粥样硬化中的调节作用:当前知识和新见解[J]. 中国结合医学杂志（英文版）, 2023,29(2):179-185.

YAO Si-jie, LAN Tao-hua, ZHANG Xin-yu, et al. LOX-1 Regulation in Anti-atherosclerosis of Active Compounds of Herbal Medicine: Current Knowledge and the New Insight[J]. Chinese Journal of Integrative Medicine, 2023,29(2):179-185.
LOX-1在中药活性化合物抗动脉粥样硬化中的调节作用:当前知识和新见解[J]. 中国结合医学杂志（英文版）, 2023,29(2):179-185. DOI： 10.1007/s11655-022-3621-9.

YAO Si-jie, LAN Tao-hua, ZHANG Xin-yu, et al. LOX-1 Regulation in Anti-atherosclerosis of Active Compounds of Herbal Medicine: Current Knowledge and the New Insight[J]. Chinese Journal of Integrative Medicine, 2023,29(2):179-185. DOI： 10.1007/s11655-022-3621-9.

摘要

凝集素样氧化低密度脂蛋白受体-1 (Lectin-like oxidized low-density lipoprotein receptor-1

LOX-1)最近被证实与动脉粥样硬化(atherosclerosis

AS)的发生、发展密切相关. 越来越多的证据表明

中医药在防治AS方面具有独特的优势. 本文就动脉粥样硬化与LOX-1的相关研究进展进行了总结. 并进一步综述了10种中药活性成分通过调控LOX-1发挥抗动脉粥样硬化的作用. 作为动脉粥样硬化潜在的生物标志物和干预靶点

LOX-1靶向治疗可能为动脉粥样硬化的预防和治疗提供一种有前途的新方法.

Abstract

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) have recently been identified to be closely related to the occurrence and development of atherosclerosis (AS). A growing body of evidence has suggested Chinese medicine takes unique advantages in preventing and treating AS. In this review

the related research progress of AS and LOX-1 has been summarized. And the anti-AS effects of 10 active components of herbal medicine through LOX-1 regulation have been further reviewed. As a potential biomarker and target for intervention in AS

LOX-1 targeted therapy might provide a promising and novel approach to atherosclerotic prevention and treatment.

关键词

动脉粥样硬化中草药凝集素样氧化低密度脂蛋白受体-1靶向治疗

Keywords

atherosclerosisherbal medicinelectin-like oxidized low-density lipoprotein receptor-1targeted therapy

references

Pothineni NVKM, Karathanasis SKP, Ding ZP, et al. LOX-1 in atherosclerosis and myocardial ischemia. J Am Coll Cardiol 2017;69:2759-2768.

Zeya B, Arjuman A, Chandra NC. Lectin-like oxidized low-density lipoprotein (LDL) receptor (LOX-1): a chameleon receptor for oxidized LDL. Biochemistry 2016;55:4437-4444.

Tian K, Ogura S, Little PJ, et al. Targeting LOX-1 in atherosclerosis and vasculopathy: current knowledge and future perspectives. Ann Ny Acad Sci 2019;1443:34-53.

Singh S, Gautam AS. Upregulated LOX-1 receptor: key player of the pathogenesis of atherosclerosis. Curr Atheroscler Rep 2019;21:38.

Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther (Oxford) 2002;95:89-100.

Gliozzi M, Scicchitano M, Bosco F, et al. Modulation of nitric oxide synthases by oxidized LDLs: role in vascular Inflammation and atherosclerosis development. Int J Mol Sci 2019;20:3294.

Pernow J, Shemyakin A, Böhm F. New perspectives on endothelin-1 in atherosclerosis and diabetes mellitus. Life Sciences (1973) 2012;91:507-516.

Morawietz H, Duerrschmidt N, Niemann B, et al. Induction of the ox-LDL receptor LOX-1 by endothelin-1 in human endothelial cells. Biochem Biophys Res Commun 2001;284:961-965.

Micaela G, Miriam S, Francesca B, et al. Brief rapid communication angiotensin Ⅱ induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Int J Mol Sci 2019;20:3294.

Dayuan L, Robin MS, Ling L, et al. Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells.Cardiovasc Res 2003;57:238-243.

Chen J, Mehta JL, Haider N, et al. Role of caspases in ox-LDL–induced apoptotic cascade in human coronary artery endothelial cells. Circ Res 2004;94:370-376.

John P, Alexey S, Felix B, et al. BcI-2 inhibition of neural death: decreased generation of reactive oxygen species.Life Sci 2012;507-516.

Yu X, Fu Y, Zhang D, et al. Foam cells in atherosclerosis.Clin Chim Acta 2013;424:245-252.

Kunjathoor VV, Febbraio M, Podrez EA, et al. Scavenger receptors class A-Ⅰ/Ⅱ and CD36 are the principal receptors responsible for the uptake of modified low-density lipoprotein leading to lipid loading in macrophages. J Biol Chem 2002;277:49982-49988.

Chistiakov DA, Bobryshev YV, Orekhov AN. Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol Med 2016;20:17-28.

Chistiakov DA, Melnichenko AA, Myasoedova VA, et al.Mechanisms of foam cell formation in atherosclerosis. J Mol Med 2017;95:1153-1165.

Ghosh S. Early steps in reverse cholesterol transport. Curr Opinion Endocrinol Diabetes Obes 2012;19:136-141.

Sun Y, Chen X. Ox-LDL-induced LOX-1 expression in vascular smooth muscle cells: role of reactive oxygen species. Fund Clin Pharmacol 2011;25:572-579.

Kataoka H, Kume N, Miyamoto S, et al. Oxidized LDL modulates Bax/Bcl-2 through the lectinlike ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001;21:955-960.

Li YY, McTiernan CF, Feldman AM. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.Cardiovasc Res 2000;46:214-224.

Dayuan L, Ling L, Hongjiang C, et al. Metalloproteinases in human coronary artery endothelial cells LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix. Circulation 2003;107:612-617.

Chen M, Kakutani M, Naruko T, et al. Activation-dependent surface expression of LOX-1 in human platelets. Biochem Bioph Res Co 2001;282:153-158.

Gu L, Bai W, Li S, et al. Celastrol prevents atherosclerosis via inhibiting LOX-1 and oxidative stress. Plos One 2013;8:65477.

Abu Bakar M, Cheng K, Sarmidi M, et al. Celastrol protects against antimycin A-induced insulin resistance in human skeletal muscle cells. Molecules 2015;20:8242-8269.

Ahmad Z, Ng CT, Fong LY, et al. Cryptotanshinone inhibits TNF-α-induced early atherogenic events in vitro. J Physiol Sci 2016;66:213-220.

Liu Z, Xu S, Huang X, et al. Cryptotanshinone, an orally bioactive herbal compound from Danshen, attenuates atherosclerosis in apolipoprotein E-deficient mice: role of lectin-like oxidized LDL receptor-1 (LOX-1). Brit J Pharmacol 2015;172:5661-5675.

Zhao W, Wu C, Chen X. Cryptotanshinone inhibits oxidized LDL-induced adhesion molecule expression via ROS dependent NF-κB pathways. Cell Adhes Migr 2016;10:248-258.

Li ZM, Xu SW, Liu PQ. Salvia miltiorrhiza Burge (Danshen): a golden herbal medicine in cardiovascular therapeutics.Acta Pharmacol Sin 2018;39:802-824.

Feng Z, Yang X, Zhang L, et al. Ginkgolide B ameliorates oxidized low-density lipoprotein-induced endothelial dysfunction via modulating lectin-like ox-LDL-receptor-1 and NADPH oxidase 4 expression and inflammatory cascades.Phytother Res 2018;32:2417-2427.

Li R, Chen B, Wu W, et al. Ginkgolide B suppresses intercellular adhesion molecule-1 expression via blocking nuclear factor-kappa B activation in human vascular endothelial cells stimulated by oxidized low-density lipoprotein. J Pharmacol Sci 2009;110:362-369.

Dong B, Wu M, Li H, et al. Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res 2010;51:1486-1495.

Ding Z, Liu S, Wang X, et al. Cross-talk between LOX-1 and PCSK9 in vascular tissues. Cardiovasc Res 2015;107:556-567.

Wang G, Liu Z, Li M, et al. Ginkgolide B mediated alleviation of inflammatory cascades and altered lipid metabolism in HUVECs via targeting PCSK-9 expression and functionality. Biomed Res Int 2019;2019:1-12.

Guan S, Wang B, Li W, et al. Effects of berberine on expression of LOX-1 and SR-BⅠ in human macrophage-derived foam cells induced by ox-LDL. Am J Chin Med 2012;38:1161-1169.

Chen FL, Yang ZH, Liu Y, et al. Berberine inhibits the expression of TNFα, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARγ pathway. Endocrine 2008;33:331-337.

Liang K, Ting C, Yin S, et al. Berberine suppresses MEK/ERK-dependent Egr-1 signaling pathway and inhibits vascular smooth muscle cell regrowth after in vitro mechanical injury. Biochem Pharmacol 2006;71:806-817.

Wang G, Shi C, Sun M, et al. Tetramethylpyrazine attenuates atherosclerosis development and protects endothelial cells from ox-LDL. Cardiovasc Drug Ther 2013;27:199-210.

Li X, He J, Liu H, et al. Tetramethylpyrazine suppresses interleukin-8 expression in LPS-stimulated human umbilical vein endothelial cell by blocking ERK, p38 and nulear factor-κB signaling pathways. J Ethnopharmacol 2009;125:83-89.

Wang P, He L, Shen G, et al. Inhibitory effects of dioscin on atherosclerosis and foam cell formation in hyperlipidemia rats. Inflammopharmacology 2017;25:633-642.

Poudel B, Lim S, Ki H, et al. Dioscin inhibits adipogenesis through the AMPK/MAPK pathway in 3T3-L1 cells and modulates fat accumulation in obese mice. Int J Mol Med 2014;34:1401-1408.

Jiang Q, Wang D, Han Y, et al. Modulation of oxidized-LDL receptor-1 (LOX1) contributes to the antiatherosclerosis effect of oleanolic acid. Int J Biochem Cell Biol 2015;69:142-152.

Lee W, Ou H, Hsu W, et al. Ellagic acid inhibits oxidized LDL-mediated LOX-1 expression, ROS generation, and inflammation in human endothelial cells. J Vasc Surg 2010;52:1290-1300.

Umesalma S, Sudhandiran G. Differential inhibitory effects of the polyphenol ellagic acid on inflammatory mediators NF-κB, iNOS, COX-2, TNF-α, and IL-6 in 1,2-dimethylhydrazine-induced rat colon carcinogenesis.Basic Clin Pharmacol 2010;107:650-655.

Ríos J, Giner RM, Marín M, et al. A pharmacological update of ellagic acid. Planta Med 2018;84:1068-1093.

Park S, Kim J, Lee E, et al. Dietary ellagic acid attenuates oxidized LDL uptake and stimulates cholesterol efflux in murine macrophages. J Nutrition 2011;141:1931-1937.

Zhang Z, Zhang D, Du B, et al. Hyperoside inhibits the effects induced by oxidized low-density lipoprotein in vascular smooth muscle cells via oxLDL-LOX-1-ERK pathway. Mol Cell Biochem 2017;433:169-176.

Kim S, Um J, Hong S, et al. Anti-inflammatory activity of hyperoside through the suppression of nuclear factor-κB activation in mouse peritoneal macrophages. Am J Chin Med (1979) 2011;39:171-181.

Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nature reviews. Mol Cell Biology 2018;19:175-191.

Yu Z, Peng Q, Li S, et al. Myriocin and d-PDMP ameliorate atherosclerosis in ApoE-/- mice via reducing lipid uptake and vascular inflammation. Clin Sci 2020;134:439-458.

Bismuth J, Lin P, Yao Q, et al. Ceramide: A common pathway for atherosclerosis? Atherosclerosis 2008;196:497-504.

Barreto J, Karathanasis SK, Remaley A, et al. Role of LOX-1 (lectin-like oxidized low-density lipoprotein receptor 1) as a cardiovascular risk predictor. Arterioscler Thromb Vascul Biol 2020;41:153-166.

Patriki D, Saravi S, Camici GG, et al. PCSK 9: a link between inflammation and atherosclerosis. Curr Med Chem 2021;29:251-267.

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Research Advance of Chinese Medicine in Treating Atherosclerosis: Focus on Lipoprotein-Associated Phospholipase A2

Quercetin Attenuates Atherosclerosis via Modulating Apelin Signaling Pathway Based on Plasma Metabolomics